CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Shao-Lee Lin

Chief Executive Officer, Cue Biopharma

Search every verified Shao-Lee Lin interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Shao-lee Lin, Chief Executive Officer of Cue Biopharma, discussed the company's clinical progress and strategic plans during recent earnings calls and media appearances. In the company's Q3 FY26 earnings call on August 14, 2026, Lin reported that the Phase 2 trial of CUE-221 in chronic spontaneous urticaria (CSU) met its primary endpoint, with statistically significant results in the high-dose group. She stated that the company plans to advance CUE-221 into a Phase 2B/3 study for CSU and a Phase 2 study for food allergy. Lin characterized the drug as having potential for disease modification, citing persistent clinical effects observed 12 weeks after the last dose, and attributed this to the molecule's engineered dual mechanism of action. In a June 2026 interview, Lin described CUE-221 as a next-generation anti-IgE program developed by the creators of Xolair, noting its additional mechanism for downregulating IgE synthesis. She highlighted food allergy as an area of significant unmet need, citing a 300% rise in prevalence over the last decade and approximately 30 million affected Americans. Lin expressed the company's goal of approaching a "functional cure" for IgE-mediated diseases, aiming for near-complete and durable protection for patients, while cautioning that patients should not alter their behavior without further clinical experience. The company also reported a Q3 FY26 EPS of $-24.14, missing estimates, with revenue of $7.9 million.

Recent appearances

  • Cue Biopharma, Inc. Q3 FY26 Earnings Call | Full Recording | CUE

    September 21, 2026 · 📺 Alfa finder USA

    Full Cue Biopharma, Inc. (CUE) Q3 FY26 earnings call — complete recording with CEO/CFO commentary and analyst Q&A. 📰 Cue Biopharma Plans Phase 2B/3 CSU Study After Q221 Meets Primary Endpoint ⚠️ Risks: Dropout rates were noted as being in range with expectations for a clinical trial of this duration and observation period. 🎯 Outlook: The company is planning a Phase 2B/3 study in CSU and a Phase 2 study for food allergy following positive Phase 2 results. Q3 FY26 Results EPS: $-24.14 (est. $-1.69) — miss Revenue: $7.9M Reported: 2026-08-14 Recent Quarters 2026-05-14: EPS $-1.08 vs est $-3.3…

    Watch on YouTube ↗

  • Can Cue Biopharma’s Anti-IgE Shot Disrupt a $4B Market?

    August 25, 2026 · 📺 The Upside With Lou Basenese

    Is this a "functional cure"? A single shot drove a key allergy marker below measurable levels and, per the CEO, held it there beyond 14 weeks. In this episode of The Upside, newly appointed Cue Biopharma CEO Dr. Shao-Lee Lin sits down with Lou Basenese to explain the science — the next-gen anti-IgE program (CUE-221) chasing chronic hives today and food allergy next, the Nobel-Prize-rooted regulatory T-cell platform (CUE-401) for autoimmune disease, the Boehringer Ingelheim partnership, and how she frames Cue Biopharma (CUE) against ~$2 billion M&A benchmarks. ▶️ More on Cue Biopharma: Websi…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →